Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.

Détails

ID Serval
serval:BIB_753ADAC383A2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS.
Périodique
British journal of haematology
Auteur(s)
Czibere A., Prall W.C., Zerbini L.F., Jäger M., Kobbe G., Knipp S., Libermann T.A., Haas R., Aivado M.
ISSN
0007-1048 (Print)
ISSN-L
0007-1048
Statut éditorial
Publié
Date de publication
11/2006
Peer-reviewed
Oui
Volume
135
Numéro
3
Pages
355-357
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The influence of Exisulind on the viability and apoptosis of CD34(+) stem cells from patients with advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML)/MDS was investigated. In eight out of 10 patient samples Exisulind reduced the fraction of viable cells by inducing apoptosis. We found evidence that Exisulind-mediated apoptosis depends on c-Jun NH(2)-terminal kinase (JNK) activation. Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS.
Mots-clé
Acute Disease, Antigens, CD34, Antineoplastic Agents/pharmacology, Apoptosis/drug effects, Cell Survival/drug effects, Cells, Cultured, Enzyme Activation, Humans, JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors, JNK Mitogen-Activated Protein Kinases/metabolism, Leukemia, Myeloid/physiopathology, Myelodysplastic Syndromes/physiopathology, Stem Cells/drug effects, Stem Cells/physiology, Sulindac/analogs & derivatives, Sulindac/pharmacology
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/07/2019 12:21
Dernière modification de la notice
21/08/2019 5:36
Données d'usage